References
- Sorenmo K. An update on canine mammary gland tumors. ACVIM Forum. 1998;16:387–8.
- Sorenmo K. Canine mammary gland tumors. Vet Clin North Am Small Anim Pract. 2003;33(3):573–96. doi:https://doi.org/10.1016/s0195-5616(03)00020-2
- Pinho SS, Carvalho S, Cabral J, Reis CA, Gärtner F. Canine tumors: a spontaneous animal model of human carcinogenesis. Transl Res. 2012;159(3):165–72. doi:https://doi.org/10.1016/j.trsl.2011.11.005
- Kitchell BE, Fidel JL. Tamoxifen as a potential therapy for canine mammary carcinoma. Proc Vet Cancer Soc. 1992;91:91–4.
- Lavalle GE, De Campos CB, Bertagnolli AC, Cassali GD. Canine malignant mammary gland neoplasms with advanced clinical staging treated with carboplatin and cyclooxygenase inhibitors. In Vivo. 2012;26(3):375–80.
- MacEwen EG, Harvey HJ, Patnaik A. Evaluation of effects of levamisole and surgery on canine mammary cancer. J Biol Resp Modif. 1985;4(4):418–26.
- Rosenthal RC. Chemotherapy. In: Ettinger SJ, Feldman EC, eds. Textbook of Veterinary Internal Medicine. 4th ed. Philadelphia, PA: W.B. Saunders Company; 1995. pp. 23–8.
- Rutterman GR, Withrow SJ, MacEwan EG. Tumors of mammary gland. In: Withrow SJ, MacEwan EG, eds. Small Animal Clinical Oncology. 3rd ed. Philadelphia, PA: WB Saunders Co; 2001. pp. 455–73.
- Aiello SE. The Merck Veterinary Manual. New York, NY: Merck&CO; 1998. pp. 1043–5.
- Rogers KS. Understanding the process of cancer metastasis. Vet Med. 1993;88(3):218–26.
- Marti JA, Fernandez S. Clinical approach to mammary gland disease. In: England G, von Heimendahl A, eds. BSAVA Manual of Canine and Feline Reproduction and Neonatology. 2nd ed. Cambridge, UK: British Small Animal Veterinary Association; 2010. pp. 155–65.
- Sleeckx N, De Rooster H, Veldhuıs Kroeze EJB, Van Gınneken C, Van Brantegem L. Canine mammary tumours, an overview. Reprod Domest Anim. 2011;46(6):1112–31. doi:https://doi.org/10.1111/j.1439-0531.2011.01816.x
- Lana SE, Dobson JM. Principles of chemotherapy. In: Dobson JM, Lascelles BDX, eds. Manual of Canine and Feline Oncology. 3rd ed. Gloucester, UK: British Small Animal Veterinary Association; 2016. pp. 59–79.
- Chun R, Garret I, Vail D. Cancer chemotherapy. In: Withrow SJ, Vail DM, eds. Withrow & MSCEwen’s Small Animal Clinical Oncology. 4th ed. Philadelphia, PA: WB Saunders; 2007. pp. 163–92.
- Misdorp W, Else RW, Hellmen E, Lipscomb TP. Histologic Classification of Mammary Tumors of the Dog and the Cat. 2nd ser., vol. 7. Washington, DC: Armed Force Institute of Pathology and World Health Organization; 1999.
- Goldschmidt M, Pena L, Rasotto R, Zappulli V. Classification and grading of canine mammary tumors. Vet Pathol. 2011;48(1):117–31. doi:https://doi.org/10.1177/0300985810393258
- Misdorp W, Cotchin E, Hampe JF, Jabara AG, von Sandersleben J. Canine malignant mammary tumours: II. Adenocarcinomas, solid carcinomas and spindle cell carcinomas. Vet Pathol. 1972;9(6):447–70. doi:https://doi.org/10.1177/030098587200900605
- von Euler H. Tumors of the mammary glands. In: Dobson JM and Lascelles BDX, eds. Manual of Canine and Feline Oncology. 3rd ed. Gloucester, British Small Animal Veterinary Association p. 237–47. 2016.
- Misdorp W, Cotchin E, Hampe JF, Jabara AG, Von Sandersleben J. Canine malignant mammary tumors. 3. Special types of carcinomas, malignant mixed tumors. Vet Pathol. 1973;10(3):241–56. doi:https://doi.org/10.1177/030098587301000307
- Rahmani AH, Alsahli MA, Aly SM, Khan MA, Aldebasi YH. Role of curcumin in disease prevention and treatment. Adv Biomed Res. 2018;7:38. doi:https://doi.org/10.4103/abr.abr_147_16
- Tomeh MA, Hadianamrei R, Zhao X. A review of curcumin and its derivatives as anticancer agents. IJMS. 2019;20(5):1033–58. doi:https://doi.org/10.3390/ijms20051033
- Perrone D, Ardito F, Giannatempo G, Dioguardi M, Troiano G, Lo Russo L, DE Lillo A, Laino L, Lo Muzio L. Biological and therapeutic activities, and anticancer properties of curcumin. Exp Ther Med. 2015;10(5):1615–23. doi:https://doi.org/10.3892/etm.2015.2749
- Panda AK, Chakraborty D, Sarkar I, Khan T, Sa G. New insights into therapeutic activity and anticancer properties of curcumin. JEP. 2017;9:31–45. doi:https://doi.org/10.2147/JEP.S70568
- Fadus MC, Lau C, Bikhchandani J, Lynch HT. Curcumin: an age-old anti-inflammatory and anti-neoplastic agent. J Tradit Complement Med. 2017;7(3):339–46. doi:https://doi.org/10.1016/j.jtcme.2016.08.002
- Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res. 2004;10(20):6847–54. doi:https://doi.org/10.1158/1078-0432.CCR-04-0744
- Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, et al. Phase 1 clinical trial of curcumin, a chemopreventive agent. Patients with high-risk of pre-malignant lesions. Anticancer Res. 2001;21(4B):2895–900.
- Nagahama K, Utsumi T, Kumano T, Maekawa S, Oyama N, Kawakami J. Discovery of a new function of curcumin which enhances its anticancer therapeutic potency. Sci Rep. 2016;6:30962. doi:https://doi.org/10.1038/srep30962
- Gera M, Sharma N, Ghosh M, Huynh DL, Lee SJ, Min T, Kwon T, Jeong DK. Nanoformulations of curcumin: an emerging paradigm for improved remedial application. Oncotarget. 2017;8(39):66680–98. doi:https://doi.org/10.18632/oncotarget.19164
- Alkan FU, Anlas C, Cinar S, Yildirim F, Ustuner O, Bakirel T, Gurel A. Effects of curcumin in combination with cyclophosphamide on canine mammary tumour cell lines. Veterinarni Medicina. 2014;59(11):553–72. doi:https://doi.org/10.17221/7820-VETMED
- Slaoui M, Fiette L. Histopathology procedures: from tissue sampling to histopathological evaluation. In: Gautier JC, eds. Drug Safety Evaluation: Methods in Molecular Biology (Methods and Protocols). New York, NY: Humana Press; 2011. pp. 671.
- Slaoui M, Bauchet AL. Fiette L: Tissue Sampling and Processing for Histopathology Evaluation. In: Gautier JC, eds. Drug Safety Evaluation: Methods in Molecular Biology (Methods and Protocols). New York, NY: Humana Press; 2017. pp. 1641.
- Misdorp W. Tumors of the mammary gland. In: Meuten DJ, ed. Tumors in Domestic Animals. 4th ed. Ames, IA: Iowa State Press; 2002. pp. 575–606.
- Kaszak I, Ruszczak A, Kanafa S, Kacprzak K, Król M, Jurka P. Current biomarkers of canine mammary tumors. Acta Vet Scand. 2018;60(1):66. doi:https://doi.org/10.1186/s13028-018-0417-1
- Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1–2):55–63. doi:https://doi.org/10.1016/0022-1759(83)90303-4
- Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods. 1995;184(1):39–51. doi:https://doi.org/10.1016/0022-1759(95)00072-i
- Guney Eskiler G, Deveci AO, Bilir C, Kaleli S. Synergistic effects of nobiletin and sorafenib combination on metastatic prostate cancer cells. Nutr Cancer. 2019;71(8):1299–312. doi:https://doi.org/10.1080/01635581.2019.1601237
- Kasibhatla S, Amarante-Mendes GP, Finucane D, Brunner T, Bossy-Wetzel E, et al. Acridine orange/ethidium bromide (AO/EB) staining to detect apoptosis. CSH Protoc. 2006;2006(3):pdb.prot4493.
- Biller B, Berg J, Garrett L, Ruslander D, Wearing R, Abbott B, Patel M, Smith D, Bryan C. 2016 AAHA Oncology Guidelines for Dogs and Cats. J Am Anim Hosp Assoc. 2016;52(4):181–204. doi:https://doi.org/10.5326/JAAHA-MS-6570
- Baba AI, Câtoi C. Mammary Gland Tumors. In: Baba AI, Câtoi C, eds. Comparative Oncology. Bucharest, Romania: The Publishing House of the Romanian Academy; 2007.
- Makki J. Diversity of breast carcinoma: Histological subtypes and clinical relevance. Clin Med Insights Pathol. 2015;8:23–31. doi:https://doi.org/10.4137/CPath.S31563
- Cragg GM, Pezzuto JM. Natural products as a vital source for the discovery of cancer chemotherapeutic and chemopreventive agents. Med Princ Pract. 2016;25(2):41–59. doi:https://doi.org/10.1159/000443404
- Hewlings S, Kalman D. Curcumin: a review of its’ effects on human health. Foods. 2017;6(10):92. doi:https://doi.org/10.3390/foods6100092
- Liu D, Chen Z. The effect of curcumin on breast cancer cells. J Breast Cancer. 2013;16(2):133–7. doi:https://doi.org/10.4048/jbc.2013.16.2.133
- Guney Eskiler G, Sahin E, Deveci Ozkan A, Cilingir Kaya OT, Kaleli S. Curcumin induces DNA damage by mediating homologous recombination mechanism in triple negative breast cancer. Nutr Cancer. 2020;72(6):1057–66. doi:https://doi.org/10.1080/01635581.2019.1670216
- Menon VP, Sudheer AR. Antioxidant and anti-inflammatory properties of curcumin. In: Aggarwal BB, Surh YJ, Shishoda S, eds. The molecular targets and therapeutic uses of curcumin in health and disease. Boston, MA: Springer; 2007. pp. 105–25.
- Jacob A, Wu R, Zhou M, Wang P. Mechanism of the anti-inflammatory effect of curcumin: PPAR-gamma activation. PPAR Res. 2007;2007:89369. doi:https://doi.org/10.1155/2007/89369
- Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51(1):27–41. doi:https://doi.org/10.1016/j.immuni.2019.06.025
- DeNardo DG, Johansson M, Coussens LM. Immune cells as mediators of solid tumor metastasis. Cancer Metastasis Rev. 2008;27(1):11–8. doi:https://doi.org/10.1007/s10555-007-9100-0
- Greten FR, Karin M. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5(10):749–59. doi:https://doi.org/10.1038/nri1703
- Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol. 2007;7(1):41–51. doi:https://doi.org/10.1038/nri1995
- Rao CV. Regulation of COX and LOX by curcumin. Adv Exp Med Biol. 2007;595:213–26.
- Eskiler GG, Ozkan AD, Kaleli S, Bilir C. Inhibition of TLR4/TRIF/IRF3 signaling pathway by curcumin in breast cancer cells. J Pharm Pharm Sci. 2019;22(1):281–91. doi:https://doi.org/10.18433/jpps30493
- Huang T, Chen Z, Fang L. Curcumin inhibits LPS-induced EMT through downregulation of NF-κB-Snail signaling in breast cancer east cancer cells. Oncol Rep. 2013;29(1):117–24. doi:https://doi.org/10.3892/or.2012.2080